## IN THIS ISSUE
Highlighted research articles

## NEWS IN BRIEF
Important news stories affecting the community

## NEWS IN DEPTH
Q&A: Mitchell Zeller on the FDA and Tobacco

## RESEARCH BRIEFS
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

## RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature

## ONLINE
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org

## VIEWS
In The Spotlight

Climbing RAS, the Everest of Oncogenes
M. Russo, F. Di Nicolantonio, and A. Bardelli
See article, p. 42

miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2α Regulation
H. Moch and M. Lukamowicz-Rajská
See article, p. 53

Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis
R.A. Brekken
See article, p. 110

## FORUM
In Focus

Towards a Unified Model of RAF Inhibitor Resistance
D.B. Solit and N. Rosen
See articles, p. 61, p. 69, p. 80, p. 94

## REVIEW
Antiangiogenic Therapies: Going beyond Their Limits
L. Moserle, G. Jiménez-Valerio, and O. Casanovas

## RESEARCH BRIEFS
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1


Précis: mTORC inhibitors decrease MCL-1 translation and cooperate with BCL-2/BCL-XL inhibitors to induce apoptosis and growth arrest in KRAS- and BRAF-mutant colorectal cancer.

See commentary, p. 19

## NEWS IN BRIEF
Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

Précis: Repression of specific miRNAs antagonizes the tumor-suppressive activity of HIF1α in ccRCC tumors by augmenting expression of the oncoprotein HIF2α.

See commentary, p. 22

## NEWS IN DEPTH
Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis
R.A. Brekken

See article, p. 110

## FORUM
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Précis: Whole-exome and transcriptome sequencing of dabrafenib- and trametinib-resistant melanomas identifies putative mechanisms of acquired resistance to combined RAF/MEK inhibition.

See commentary, p. 27
Using data from a high-throughput drug screen, Faber and colleagues found that AZD8055, an inhibitor of mTOR complexes 1 and 2 (TORC1/2), cooperated with the BCL-2/BCL-XL inhibitor ABT-263 to induce cell-cycle arrest and apoptosis specifically in KRAS- and BRAF-mutant colorectal cancer cell lines. This genotype selectivity was mediated by suppression of the antiapoptotic protein MCL-1 and disruption of BIM–MCL-1 complexes in response to TORC1/2 inhibition, which sensitized KRAS-mutant cells to ABT-263 and triggered apoptosis. Furthermore, dual treatment with ABT-263 and AZD8055 preferentially induced tumor regression in KRAS-mutant colorectal cancer xenograft and genetically engineered mouse models. These results support further clinical development of this therapeutic combination for patients with KRAS- and BRAF-mutant colorectal cancer. For details, please see the article by Faber and colleagues on page 42.
Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/4/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.